1 videos available from ASCO
51:12
POST ASCO 2026 Updates
Join Moaath Mustafa Ali, MD, and Adeel Khan, MD, as they discuss the highlights from ASCO 2026, offering expert perspectives on the latest research and its clinical implications.
Key Learning Points:
- Selinexor plus ruxolitinib nearly doubles SVR35 in JAK-inhibitor-naive myelofibrosis, with greater reduction in driver-gene VAF, though symptom improvement is unchanged
- An early overall survival signal favors the selinexor combination, but the benefit is limited to patients with platelets above 100,000, excluding cytopenic later-stage disease
- The azacitidine, venetoclax, and ivosidenib triplet achieves high response and MRD-negativity rates in newly diagnosed IDH1-mutated AML with minimal early mortality
- +7 more points...
2026
Jul 1, 2026